DTHF WELCOMES EARLY DATA FROM ENSEMBLE TRIAL, SHOWING SAFETY & EFFICACY FOR SINGLE -SHOT JANSSEN COVID-19 VACCINE CANDIDATE

Johnson & Johnson today announced topline efficacy and safety data from the Phase 3 ENSEMBLE clinical trial, demonstrating its investigational single-dose COVID-19 vaccine met all primary and key secondary endpoints. The topline safety and efficacy data are based on 44,325 44 participants accruing 468 symptomatic cases of COVID-19. The Desmond Tutu Health Foundation is a…

Efficacy Results announced: global first Antibody Mediated Prevention (AMP) trials

Most advanced clinical trials testing broadly neutralizing antibody against HIV demonstrate efficacy against sensitive strains.   The proof-of-concept AMP studies demonstrated that a broadly neutralizing antibody (bnAb) called VRC01 was effective at preventing the acquisition of HIV strains that were sensitive to the bnAb. This was assessed by a laboratory test that measures a virus’…